Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study-Reference-Cited by-同舟云学术

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

Published:2023-04 Issue:10382 Volume:401 Page:1091-1102
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Lederman Samuel,Ottery Faith D,Cano Antonio,Santoro Nanette,Shapiro Marla,Stute Petra,Thurston Rebecca C,English Marci,Franklin Catherine,Lee Misun,Neal-Perry Genevieve

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation;Gold;Am J Public Health,2006

2. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort;Freeman;Menopause,2014

3. The 2017 hormone therapy position statement of The North American Menopause Society;Menopause,2017

4. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review;Utian;Health Qual Life Outcomes,2005

5. Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women's Health Across the Nation;Avis;Menopause,2009

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Infertility Management through Novel Peptide-basedTargets;Current Protein & Peptide Science;2024-11

2. Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-11

3. Neuroendocrine mechanisms of mood disorders during menopause transition: A narrative review and future perspectives;Maturitas;2024-10

4. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10

5. Survey of patient experience and management of vasomotor symptoms due to menopause from the PatientsLikeMe community;Menopause;2024-09-10